Xiaohui Zhao

Xiaohui Zhao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
JYJuan Yang
Juan Yang
LWLingling Wang
Lingling Wang
HLHuiqin Liu
Huiqin Liu
HXHui Xu
Hui Xu
FLFeng Liu
Feng Liu
HLHongqiang Li
Hongqiang Li

1 January 2018 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
YWYong-Bing Wang
Yong-Bing Wang
JLJie Ling
Jie Ling
WZWen-Zhong Zhang
Wen-Zhong Zhang
GLGang Li
Gang Li
WQWei Qiu
Wei Qiu
XZXiaohui Zhao
Xiaohui Zhao
The effect of bisacodyl on the treatment of rats with slow transit constipation (STC) was studied. Forty-five female Wister rats were divided into control group, STC group, and STC bisacodyl group. The immunohistochemical method was used to determine interstitial cells of Cajal (ICC) and the expression of c-Kit protein. Body mass and the number of defecations were significantly decreased in the STC group compared with the control group on the 100th day after diphenoxylate administration, while dry weight of feces was significantly increased and the intestinal transit time was prolonged. There were significant differences in the number of defecations, dry weight of feces, and intestinal transit time among the three groups. The number of defecations was higher, dry weight of feces was lower, and intestinal transit time was shorter in the STC bisacodyl group compared to the STC group. In addition, ICC basement membrane dissolution occurred in the colon wall of the STC group. The connection between ICC and surrounding cells was destroyed, and the nucleus shrunken to different degrees. Moreover, c-Kit expression in the STC group was significantly lower than the control group. The connection between ICC and surrounding cells in the STC bisacodyl group was significantly stronger than the STC group, and the number of ICC and the expression of c-Kit were increased. Bisacodyl could reduce the severity of STC in rats by increasing the number of ICC and the expression of c-Kit.

1 January 2024 in Neurology India
Verified
Journal Article
Open access
JYJuan Yang
Juan Yang
HSHaijing Sui
Haijing Sui
HSHaihan Song
Haihan Song
RJRonghong Jiao
Ronghong Jiao
XZXiaohui Zhao
Xiaohui Zhao
Background and Objective: Previous literature has reported that red cell distribution width (RDW) correlated with Alzheimer’s disease (AD), but the correlation with mild cognitive impairment (MCI) was not clear. This study aimed to investigate MCI in the residents aged ≥65 living in the suburban of Shanghai, China. Materials and Methods: A total of 550 participants were recruited as MCI (MCI group, 226) and normal (NC group, 284) groups and received blood examination voluntarily. Blood routine indexes were tested by blood tests using Sysmex XT-4000i (Japan). The Chi-square test, t-test, and linear regression analysis were used to find the statistical difference and correlation of data, respectively. Results: Each cognition domain of MCI was found to be impaired, the weight of which, however, was different in integral damage. Most MCI people had impairment of attention among cognitive domains (235, 88.3%). According to the results of the binary logistic regression, the highest weight among impaired cognitive domains was for attention in MCI, and the Wald value of attention was higher than those of others (Wald = 51.83). Additionally, RDW had the greatest negative correlation with attention score (P < 0.05). Conclusions: Increased RDW may be considered as a biomarker of MCI.

9 July 2025 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
YZYuwen Zhao
Yuwen Zhao
LLLin Li
Lin Li
DHDongya Huang
Dongya Huang
WLWentao Li
Wentao Li
QZQiuyan Zhao
Qiuyan Zhao
ZLZhenguo Liu
Zhenguo Liu
Depression is a prevalent non-motor symptom of Parkinson’s disease (PD) that significantly impacts patients’ quality of life. The Wuling capsule, a traditional Chinese medicine, is often utilized for treating depression, and this herbal medicine has been used to treat those PD patients with depression. This study aims to assess the efficacy and safety of Wuling capsule in treating mild depression in patients with early PD. This multicenter, double-blind, placebo-controlled randomized clinical trial included 160 patients with early PD who presented with a Hamilton Rating Scale for Depression (HAMD) score between 8 and 17 at the time of admission. The trial was conducted across five hospitals in China from December 2021 to March 2024. Eligible patients were randomly assigned to receive either Wuling capsule (0.99 g orally three times daily) or a placebo (0.99 g orally three times daily) for a duration of 12 weeks. Additional treatment according to established clinical guidelines.The primary outcome measure was the change in HAMD score. All statistical analyses were conducted on an intention-to-treat population. After 12 weeks of treatment, among the 160 patients with early PD and depression, 80 were assigned to the Wuling capsule group and 80 to the placebo group, with the median age of 70.5 (IQR,67.00–75.00) years and 77 (48.13%) were male. Patients in the Wuling capsule group demonstrated significantly greater reductions in depression severity compared to the placebo group at multiple time points: week 4 (difference, − 1.21 [95% CI, -2.38 to -0.04; P = 0.042]), week 8 (difference, − 1.41 [95% CI, -2.81 to -0.02; P = 0.047]), and week 12 (difference, − 1.46 [95% CI, -2.89 to -0.04; P = 0.044]). Adverse events were reported in 3 of 80 patients (3.75%) in the Wuling capsule group and 3 of 80 patients (3.75%) in the control group (P = 1), indicating no significant difference. This randomized clinical trial demonstrated that treatment with Wuling capsule over a 12-week period effectively reduced HAMD score in patients with mild depression associated with PD and the treatment was well tolerated. Chinese Clinical Trial Registry; registration number: ChiCTR2100046195; prospectively registered on May 9th, 2021.